Methods and compositions for early cancer testing and cancer diagnosis before the clinical symptoms of malignant diseases and the method and component

A cancer, malignant technology, applied in chemical instruments and methods, biochemical equipment and methods, analytical materials, etc., can solve problems such as undetermined cell surface ENOX2 cancer specificity

Active Publication Date: 2021-04-02
MOR NUCO ENTERPRISES
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Although the basis for the cancer specificity of cell surface ENOX2 has not been previously identified, this concept is supported by several lines of evidence

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for early cancer testing and cancer diagnosis before the clinical symptoms of malignant diseases and the method and component
  • Methods and compositions for early cancer testing and cancer diagnosis before the clinical symptoms of malignant diseases and the method and component
  • Methods and compositions for early cancer testing and cancer diagnosis before the clinical symptoms of malignant diseases and the method and component

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0137] Example 1. As determined by 2-D gel electrophoresis / immunoblotting analysis, the two-fold increase in the spot size and density of different amounts of ENOX2 in the assay, compared with no NADH in the presence of 15 μM NADH incubation ( figure 1 ).

Embodiment 2

[0138] Example 2. Analysis of sera from 1,626 cancer patients with diagnosed cancer (Table 1, reproduced from Summary of the Invention) showed transcript variants (Protein 1 to Non-overlapping patterns of protein3) quantities, molecular weights, and isoelectric points.

[0139] Table 1, reproduced from Summary of the Invention: Molecular weight (MW) and isoelectric point (Pi) ranges determined for sera from patients diagnosed with 24 different cancers representing 20 different tissues of origin

[0140]

[0141]

[0142] * Blood cell cancers include lymphomas, leukemias, and myelomas expressed as totals.

[0143] **Non-small cell lung cancer in two subsets to avoid molecular weight overlap with small cell lung cancer.

[0144] ***Uterine cancer in two subsets based on molecular weight to avoid overlap with bladder cancer (see footnotes 1 and 2).

[0145] 1. The isoelectric point pH of protein 1 ≥ protein 2.

[0146] 2. The isoelectric point pH of protein 1 < protein 2...

Embodiment 3

[0147] Example 3. The ONCOblot test correctly identifies cancers based on tissue of origin with stage 0 and stage I cancers (Table 3). Stage 0 and I cancers are often called carcinoma in situ, and the disease has not spread beyond the tissue in which it originated. Therefore, the ONCOblot cancer test indicates cancer earlier than the circulating tumor cell test, which detects only cancer cells in the blood.

[0148] Table 3. Tissues of origin for stage 0 and stage I cancers analyzed

[0149]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
diameteraaaaaaaaaa
Sensitivityaaaaaaaaaa
Login to view more

Abstract

The invention includes a method for detecting benign to malignant transformation of cancer in a subject comprising the steps of: collecting a sample from the subject prior to electrophoretic protein separation; activating electrophoretic separation of ENOX2 transcription using an ENOX2 electron donor and detecting the presence of one or more activated ENOX2 transcript variants using a pan-ENOX2 detectable binding reagent, wherein the presence of the one or more activated ENOX2 transcript variants in the sample indicates malignant transformation of the cancer, Thereby a 10 to 100-fold increase in the detection sensitivity of one or more activated ENOX2 transcript variants is obtained when compared to an equivalent non-activated ENOX2 transcript variant.

Description

technical field [0001] The present invention relates generally to the field of cancer detection and diagnosis, and more specifically to a functionalized single chain variable region recombinant ENOX2 antibody based on NADH-targeted detection. [0002] Incorporate material submitted on CD-ROM as a reference [0003] This application includes a Sequence Listing submitted via EFS-Web in ASCII format, which is hereby incorporated by reference in its entirety. Said ASCII copy, created on May 30, 2016, is named MNCE1002.txt and is 18kb in size. Background technique [0004] Without limiting the scope of the invention, its background is described in connection with cancer protein biochemistry. [0005] There is a distinct, growth-associated family of cell surface hydroquinone or NADH oxidases with protein disulfide-sulfhydryl interchange activity, called ECTO-NOX proteins (for cell surface NADH oxidase) (Morre, 1998. Plasma Membrane Redox Systems and Their Role in Biological St...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/68
CPCG01N33/574G01N33/6893C12Q1/26G01N33/561G01N33/57492C12Y106/00G01N33/57488G01N2333/47C07K16/40C07K2317/56C07K2317/622G01N21/49G01N2333/90209
Inventor D.J.摩尔
Owner MOR NUCO ENTERPRISES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap